1101 related articles for article (PubMed ID: 28527985)
1. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
[TBL] [Abstract][Full Text] [Related]
2. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Leukemia; 2016 Feb; 30(2):261-7. PubMed ID: 26283567
[TBL] [Abstract][Full Text] [Related]
3. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
[TBL] [Abstract][Full Text] [Related]
4. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Chevallier P; Labopin M; Socié G; Tabrizi R; Furst S; Lioure B; Guillaume T; Delaunay J; de La Tour RP; Vigouroux S; El-Cheikh J; Blaise D; Michallet M; Bilger K; Milpied N; Moreau P; Mohty M
Haematologica; 2014 Sep; 99(9):1486-91. PubMed ID: 24951467
[TBL] [Abstract][Full Text] [Related]
5. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.
Mohty M; Malard F; Blaise D; Milpied N; Socié G; Huynh A; Reman O; Yakoub-Agha I; Furst S; Guillaume T; Tabrizi R; Vigouroux S; Peterlin P; El-Cheikh J; Moreau P; Labopin M; Chevallier P
Haematologica; 2017 Jan; 102(1):184-191. PubMed ID: 27561720
[TBL] [Abstract][Full Text] [Related]
6. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Stelljes M; Middeke JM; Bug G; Wagner-Drouet EM; Müller LP; Schmid C; Krause SW; Bethge W; Jost E; Platzbecker U; Klein SA; Schubert J; Niederland J; Kaufmann M; Schäfer-Eckart K; Schaich M; Baldauf H; Stölzel F; Petzold C; Röllig C; Alakel N; Steffen B; Hauptrock B; Schliemann C; Sockel K; Lang F; Kriege O; Schaffrath J; Reicherts C; Berdel WE; Serve H; Ehninger G; Schmidt AH; Bornhäuser M; Mikesch JH; Schetelig J;
Lancet Haematol; 2024 May; 11(5):e324-e335. PubMed ID: 38583455
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
9. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
Magenau J; Westervelt P; Khaled S; McGuirk J; Hari P; Eapen M; Becker PS; Parkin B; Braun T; Logan B; Wang H; Jagasia M; Rowley SD; Kim DD; Schechter T; Frey N; Scott B; Churay T; Lieland S; Forman S; Mineishi S
Bone Marrow Transplant; 2017 Jan; 52(1):59-65. PubMed ID: 27427921
[TBL] [Abstract][Full Text] [Related]
10. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Stahl M; DeVeaux M; Montesinos P; Itzykson R; Ritchie EK; Sekeres MA; Majhail N; Barnard J; Podoltsev NA; Brunner AM; Komrokji RS; Bhatt VR; Al-Kali A; Cluzeau T; Santini V; Roboz GJ; Fenaux P; Litzow M; Fathi AT; Perreault S; Kim TK; Prebet T; Vey N; Verma V; Kobbe G; Bergua J; Serrano J; Gore SD; Zeidan AM
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1754-1758. PubMed ID: 29649620
[TBL] [Abstract][Full Text] [Related]
12. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
Locke FL; Artz A; Rich E; Zhang Y; van Besien K; Stock W
Bone Marrow Transplant; 2010 Dec; 45(12):1692-8. PubMed ID: 20208570
[TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
Steckel NK; Groth C; Mikesch JH; Trenschel R; Ottinger H; Kordelas L; Mueller-Tidow C; Schliemann C; Reicherts C; Albring JC; Silling G; Schmidt E; Berdel WE; Lenz G; Ditschkowski M; Beelen DW; Stelljes M
Br J Haematol; 2018 Mar; 180(6):840-853. PubMed ID: 29468631
[TBL] [Abstract][Full Text] [Related]
17. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
El-Jawahri A; Li S; Ballen KK; Cutler C; Dey BR; Driscoll J; Hunnewell C; Ho VT; McAfee SL; Poliquin C; Saylor M; Soiffer RJ; Spitzer TR; Alyea E; Chen YB
Biol Blood Marrow Transplant; 2016 Jan; 22(1):80-5. PubMed ID: 26260679
[TBL] [Abstract][Full Text] [Related]
18. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
Kirschbaum MH; Stein AS; Popplewell L; Delioukina M; Chen R; Nakamura R; Snyder D; Conrad J; Lacey SF; Frankel P; Dagis A; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):432-40. PubMed ID: 21801703
[TBL] [Abstract][Full Text] [Related]
19. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
